Search

Displaying results 5771 - 5780 of 10000 in total
  1. Drug

    Vicasinabin

    go.drugbank.com/drugs/DB21587
    Investigational

    Vicasinabin has a monoisotopic molecular weight of 358.2 Da. … Vicasinabin is under investigation in clinical trial NCT04265261 (A Study to Investigate the Efficacy and Safety of RG7774 in Patients With Diabetes Mellitus Type 1 or Type 2 With Treatment-Naive Diabetic

  2. Drug

    Cefacetrile

    go.drugbank.com/drugs/DB01414
    InvestigationalVet approved

    A derivative of 7-aminocephalosporanic acid.

    Products: CELOR ENTRAVENÖZ AMPUL 2G, 1 ADET, CELOR ENTRAVENÖZ AMPUL 2G, 5 ADET
  3. Drug

    Bafilomycin A1

    go.drugbank.com/drugs/DB06733
    Experimental

    The bafilomycins refer to a category of toxic macrolide antibiotics that are derivatives of Streptomyces griseus. … This is a useful tool as it can prevent the re-acidification of synaptic vesicles once they have undergone exocytosis.

  4. Drug

    Black widow spider antivenin (equine)

    go.drugbank.com/drugs/DB14113
    Approved

    Black widow spider (_Latrodectus mactans_) antivenin is a treatment for black widow spider bites derived from the serum of healthy horses immunized against black widow spider venom.[L12792]

  5. Drug

    Rebaudioside A

    go.drugbank.com/drugs/DB15136
    Investigational

    Rebaudioside A is under investigation in clinical trial NCT03510624 (Acute Effect of Rebaudioside A on Glucose Excursion During an Oral Glucose Tolerance Test in Type 2 Diabetes Mellitus).

  6. Drug

    Silmitasertib

    go.drugbank.com/drugs/DB15408
    Investigational

    Silmitasertib is under investigation in clinical trial NCT03904862 (Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery).

  7. Drug

    CLX-0921

    go.drugbank.com/drugs/DB05854
    Experimental

    CLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the protein peroxisome proliferator-activated receptor gamma.

  8. Drug

    ARC183

    go.drugbank.com/drugs/DB05124
    Experimental

    resolution of anticoagulation or that require reversal of anticoagulation shortly after the procedure is completed. … The key advantage of ARC183 compared to other thrombin inhibitors is its rapid onset of action and short half-life, giving it the potential to be an ideal agent for medical procedures that require rapid

  9. Drug

    Zastaprazan

    go.drugbank.com/drugs/DB21524
    Investigational

    The usage of the INN stem '-prazan' in the name indicates that Zastaprazan is a proton pump inhibitor, not dependent on acid activation. … Zastaprazan has a monoisotopic molecular weight of 362.21 Da.

  10. Drug

    Ocedurenone

    go.drugbank.com/drugs/DB21519
    Investigational

    Ocedurenone has a monoisotopic molecular weight of 503.21 Da. … Ocedurenone is under investigation in clinical trial NCT04968184 (Efficacy and Safety of KBP-5074 in Uncontrolled Hypertension and Moderate or Severe Chronic Kidney Disease (CKD)).